PureTech Health plc (LON:PRTC – Get Free Report) shares passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of GBX 116.86 and traded as high as GBX 119.20. PureTech Health shares last traded at GBX 119.20, with a volume of 7,430,262 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One analyst has rated the stock with a Buy rating. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of GBX 508.
Read Our Latest Research Report on PureTech Health
PureTech Health Stock Up 0.2%
The company has a current ratio of 4.60, a quick ratio of 2.51 and a debt-to-equity ratio of 4.78. The firm’s 50 day simple moving average is GBX 116.85 and its two-hundred day simple moving average is GBX 123.66. The firm has a market cap of £288.82 million, a price-to-earnings ratio of -2.34 and a beta of 0.77.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Featured Stories
- Five stocks we like better than PureTech Health
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
